COMPANY

bioAffinity Technologies

HQ: San Antonio, TX source · bioaffinitytech.com ↗ · Southwest

Keywords: diagnostics oncology siRNA Lung Cancer Lung Cancer (Diagnosis) CyPath®

Location: San Antonio, TX · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Sep 30, 2026 Partnership Partnership / licensing announced Sep 30, 2026. Source: SEC filing. source ↗
Feb 25, 2026 Trial start Not phased (device or behavioral study): Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer i source ↗
Sep 30, 2025 Raise Follow-on offering: $4.8M (total, as published), announced Sep 30, 2025. Source: SEC filing. source ↗
Oct 18, 2024 Raise Follow-on offering — Registered direct: $2.66M (total, as published), announced Oct 18, 2024. Source: SEC filing. source ↗
2023-08 Trial start —: Detection of Abnormal Respiratory Cell Populations in Lung Cancer Screening Patients Using the CyPath Lung Assay source ↗
Mar 1, 2018 Trial start —: Collection of Sputum and Labeling for Lung Cancer source ↗
Sep 22, 2016 Trial start —: Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer source ↗
2015-03 Trial start Not phased (device or behavioral study): Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer source ↗

Apr 1, 2029 (ESTIMATED) · Not phased · Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in Hig · NCT07168993

Estimated primary completion per ClinicalTrials.gov. Dates move.

Raised: $7.5M. Last 2 years.

Sep 30, 2025 Follow-on offering: $4.8M (total, as published), announced Sep 30, 2025. Source: SEC filing. source ↗
Oct 18, 2024 Follow-on offering — Registered direct: $2.66M (total, as published), announced Oct 18, 2024. Source: SEC filing. source ↗
Sep 30, 2026 Partnership / licensing announced Sep 30, 2026. Source: SEC filing. source ↗

Record	Title	Phase	Status	Start	Primary completion
NCT07168993	Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.	Not phased (device or behavioral study)	Recruiting	Feb 25, 2026	Apr 1, 2029 (estimated)
NCT03457415	Collection of Sputum and Labeling for Lung Cancer	Not listed	Recruiting	Mar 1, 2018	2025-12 (estimated)
NCT03837600	Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphyrin (TCPP) for Detection of Lung Cancer	Not listed	Completed	Sep 22, 2016	Aug 15, 2018 (actual)
NCT05870592	Detection of Abnormal Respiratory Cell Populations in Lung Cancer Screening Patients Using the CyPath Lung Assay	Not listed	Unknown status (ClinicalTrials.gov)	2023-08	2024-03 (estimated)
NCT02388074	Sputum Labeling Utilizing Synthetic Meso-Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer	Not phased (device or behavioral study)	Completed	2015-03	2015-04 (actual)

Form D raises come from the company’s own SEC filing (last 2 years).

2024-10-29 Raise Private raise (SEC Form D): amount sold not stated; issuer “bioAffinity Technologies, Inc.”. Verified from the SEC filing. SEC filing ↗